NeuroCycle Therapeutics, Inc.
Innovative drugs that target the central nervous system
Neurocycle Therapeutics is developing drugs that regulate neuron signaling. Our lead candidate NCT-10004 is being developed for treatment of itch in people and dogs. In addition, we have drug discovery programs in pain and orphan epilepsies.
Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
No news
No milestones
No Jobs
No videos and documents
Venture Kick
Venture Kick supports potential entrepreneurs with start capital up to CHF 150'000 as well as hands-on execution support and access to a nationwide network of investors and experts in the startup field. Multiple times per year, 8 selected projects get the opportunity to present their business ideas in front of a panel. The 5 most promising projects enter the support process. After 9 months at the latest, the startups incorporate and enter the market. Since 2007, Venture Kick has invested over CHF 58 million in over 1111 projects.
NeuroCycle Therapeutics, Inc.
Innovative drugs that target the central nervous system
Website:
www.neurocycletherapeutics.com
Engrail Therapeutics
Headquarter:
Cambridge
Foundation Date:
April 2016
Technology:
- Biotech
Sectors:
- Biotech
- Drug discovery
- Neurology
- Small molecule drugs
Support received
